Bahman Shamloo, MD
Anesthesiology · Los Angeles, CANPI 1871760918
Payments from drug & device makers
Across 482 payments — averaging $24.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Abbott$947
- Johnson & Johnson$856
- Stimwave Technologies Incorporated$589
- Takeda Pharmaceuticals U.S.A., Inc.$553
- plus $5K from 51 others
What the payments were for
- Speaking & faculty fees$40%
- Food & beverage$11,556100%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$677
- SUPERION$402
- Proclaim Family of SCS IPGs$315
- SPECTRA WAVEWRITER$245
- GENERAL PAIN MANAGEMENT$220
- XEOMIN$140
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$138
- TRULANCE$137
- Senza Spinal Cord Stimulation System$123
- PEAK$117
- MONOVISC$114
- INTELLIS ADAPTIVESTIM$112
- Zilretta$109
- Skyrizi$106
How this compares
$11,594 in reported general payments places this provider in the 95th percentile of 5,717 anesthesiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $540 |
| Celecoxib | 22 | $533 |
| Pregabalin | 17 | $404 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $320 |
| Tizanidine Hcl | 46 | $194 |
| Meloxicam | 48 | $136 |
| Gabapentin | 28 | $116 |
| Tramadol Hcl | 19 | $17 |
Paid to pharmacies, not to this prescriber.
Other anesthesiology in Los Angeles
- Eilon GabelLos Angeles$1.2M
- Maxime CannessonLos Angeles$759K
- Moody MakarLos Angeles$252K
- Jonathan JahrLos Angeles$223K
- Anahat DhillonLos Angeles$184K
- Michael BottrosLos Angeles$182K
- David BoldtLos Angeles$153K
- Kamal MaheshwariSacramento$1.9M
- Gregory HammerStanford$1.8M
- Neal FlemingSacramento$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.